CLS is committed to providing the media with timely and accurate information related to California’s life sciences ecosystem. CLS welcomes all media inquiries from news organizations and reporters. Members of the media interested in speaking with CLS opinion leaders on issues of public policy, life sciences innovation, or issues related to the life sciences ecosystem in California, please contact our communication department.
Media Contact: [email protected]
Six California startups selected for premier life sciences advisory program
Sep 2, 2022
September 2, 2022 SAN FRANCISCO, SAN DIEGO, LOS ANGELES, SACRAMENTO, Calif. – California Life Sciences (CLS), the state’s most impactful life sciences membership organization, announced today the six California startups..
Read More CLS FAST International hosts a successful two-day program with University of Edinburgh and University of Strathclyde
Aug 26, 2022
August 26, 2022 As a collaboration between California Life Sciences (CLS) and the Healthcare Technology Accelerator Facility (HTAF) at University of Edinburgh, the CLS team had the pleasure of hosting..
Read More California Life Sciences releases statement after passage of the Inflation Reduction Act
Aug 12, 2022
August 12, 2022 SOUTH SAN FRANCISCO, LOS ANGELES, SAN DIEGO, WASHINGTON D.C. — California Life Sciences (CLS), the state’s most influential life sciences membership organization, released the following statement after..
Read More Three new startups to participate in the Kansai Life Science Accelerator Program 2022
Aug 8, 2022
August 8, 2022 Kansai Life Science Accelerator Program (KLSAP), launched in 2020, is co-hosted by the City of Kobe, Foundation for Biomedical Research and Innovation at Kobe (FBRI), Bayer Yakuhin,..
Read More Congressional Efforts on Prescription Drugs Imperil Patients and Life Sciences Innovation in California
Aug 5, 2022
Until recently, there was no treatment for lung cancer patients with the aggressive KRAS G12C mutation, one of the most prevalent drivers of lung cancer. The mutation was considered “undruggable”..
Read More OPEN LETTER: 31 biopharmaceutical CEOs urge Congress to protect the life sciences industry
Aug 4, 2022
August 4, 2022 California Representatives and Senators U.S. Congress Washington, DC We write as the leadership of small and emerging biopharmaceutical companies in California that represent the leading edge of..
Read More